United States: Witnesses At Congressional Hearing On 340B Urge Congress To Give HRSA Broader Regulatory Authority

Last Updated: July 27 2017
Article by Ellyn Sternfield

On July 18, 2017, just days after CMS went public with its proposal to reduce Medicare Part B reimbursement to certain 340B covered entities, Congress held its first hearing on 340B Program Oversight since March 2015. A common thread ran through the testimony of the three testifying witnesses: Erin Bliss, Assistant Inspector General with HHS-OIG; Dr. Debra Draper, Director of Health Care at the GAO; and, Captain Krista Pedley, Director of the Office of Pharmacy Affairs at HRSA: Congress needs to legislatively grant HRSA more administrative authority over the 340B Drug Discount Program.

Captain Pedley, Dr. Draper, and a prior HHS-OIG official testified before this same Committee at a March 2015 hearing. During that hearing, HHS-OIG and the GAO expressed concerns about the explosive growth in the 340B Program as well as HRSA's oversight efforts, but made no unified endorsement of Congressional action. What changed?

I have written, ad nauseum, about the impact of the October 2015 federal court ruling invalidating regulations interpreting the statutory orphan drug exception to 340B. The court found that because the 340B statute was unambiguous, HRSA lacked authority to engage in rulemaking in areas unauthorized by Congress. In my opinion, the orphan drug ruling was directly responsible for HRSA's withdrawal of its "340B Mega-Reg" which would have set parameters for 340B Program compliance, as well as HRSA's withdrawal of similar "340B Omnibus Guidance" in early 2017.

Validation did come during the June 18th hearing. Specifically, Captain Pedley testified that HSRA had undertaken rulemaking in all areas in which the 2015 federal court ruling found that it had specific delegated authority under the 340B statute. Captain Pedley went on to note, however, that:

Specific legislative authority to conduct rulemaking for all provisions in the 340B statute would be more effective for facilitating HRSA's oversight over, and management of, the 340B Program. In addition, [a Congressional grant of] specific regulatory authority would allow HRSA to provide greater clarity and specificity to Program requirements.

Dr. Draper used her testimony to address the following four recommendations that the GAO first made to HRSA in 2011 and that she later referenced in her 2015 testimony:

  1. increase HRSA auditing for compliance;
  2. update 340B guidance for manufacturers;
  3. provide more specificity and clarity in the standards for 340B hospital eligibility; and
  4. provide more specificity and clarity in the definition of a 340B patient.

Dr. Draper acknowledged that HRSA had acted on the first two recommendations, but that it had pulled back on its efforts to act on the latter two in the wake of the 2015 ruling. Dr. Draper also raised the differing interpretations of the intent of the 340B Program, questioning whether the program's purpose is, in part, to require covered entities and contract pharmacies to provide uninsured patients with access to 340B drugs.

Ms. Bliss reiterated HHS-OIG's concerns about the lack of clarity in the rules governing the 340B Program. She also repeated a point that HHS-OIG made in the 2015 hearing: the lack of state Medicaid program access to information about 340B pricing hinders states from ensuring that Medicaid Programs are not paying more than the ceiling price for 340B drugs provided to Medicaid beneficiaries. Ms. Bliss supported congressional action to provide HRSA the necessary authority to clarify program rules, but stated that Congress also needed to authorize HRSA to share ceiling prices with state Medicaid Programs. Ms. Bliss did comment, however, that in areas where HRSA already had authority, action had been slow. She specifically questioned HRSA's efforts to implement a long-promised database for sharing 340B ceiling prices with covered entities, as well as the agency's efforts to update the processes to screen for duplicate discounts in Medicaid and Medicaid managed care.

Most of the Committee's questions were directed at Captain Pedley.

  • Perhaps as many as 10 different questions were raised about how covered entities use 340B revenues. Captain Pedley used these questions to reiterate the fact that the 340B statute does not specifically constrain a covered entity's use of 340B revenue, nor does the statute authorize HRSA to inquire or collect information on use of the revenue.
  • Captain Pedley was asked about the mechanisms through which covered entities share 340B revenues with contract pharmacies. She again pointed to a lack of HRSA authority to examine those business arrangements.
  • In response to the issues raised by HHS-OIG, Captain Pedley stated that HRSA was "getting close" and "in the coming months" would implement the ceiling price verification system for covered entities. She would not, however, commit to that implementation occurring before the end of 2017. On the issue of duplicate discounts in Medicaid managed care, she indicated that HRSA was studying the issue and that it intended to "develop policy" that would in turn be used to "develop a mechanism" to implement such policy. Captain Pedley implied that such an effort could be hampered by the statute's silence on HRSA's authority to address duplicate discounts through regulation.

Several questions were posed to the government panelists about the CMS proposal to reduce Medicare Part B reimbursement, released on July 13th. The panelists were able to dodge the question since there was no CMS representative and they were not privy to CMS's reasons for issuing the proposal.

What is Next?

The 340B program will remain a hotbed of activity in coming months. Below are some of the issues that will likely arise:

  • The clock is now running on the CMS proposal to change Medicare Part B reimbursement for 340B drugs paid to hospitals, Community Mental Health Centers, and Ambulatory Surgical Centers. The deadline for comments is September 11, 2017. As I noted in my previous post on the proposal, CMS stated it is not implementing the proposal through rule-making. Rather, CMS asserts that it has existing authority to "adjust" Medicare payments for outpatient drugs under 42 U.S.C. § 1395I(t)(14)(A)(iii)(II).
  • As part of her July 18th testimony, Dr. Draper announced that GAO has studied and will be issuing a report addressing the extent to which 340B covered entities use contract pharmacies; the types of financial arrangements that exist between covered entities and those pharmacies; the extent to which contract pharmacies provide 340B discounted drugs to low income, uninsured patients; and, compliance concerns involving 340B contract pharmacies.
  • There appeared to be a consensus among legislators that Congress needed to increase HRSA's administrative authority in 340B. However, short of giving HRSA authority to require 340B covered entities to report on the use of 340B-generated revenues, and likely giving state Medicaid programs access to 340B pricing information, it is not clear there is consensus on the breadth of the authority that should be granted to HRSA to regulate the program. Further hearings may be in the offing.
  • Rumor has it that we have not heard the last of a potential Executive Order on Drug Pricing that may, or may not, include provisions targeting 340B. The last report circulating in DC was that the section of the Order specific to 340B – which would require HHS to rescind or revise administrative actions that have purportedly "allowed" the benefits of the 340B program to accrue to individuals and entities other than the vulnerable citizens the program was intentionally intended to help – had been pulled but could still be reinserted or even strengthened.

So, as I wrote last week, when it comes to 340B there is only one thing that is certain: the future of the 340B program is uncertain. Stay tuned.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Ellyn Sternfield
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions